Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.

Background: Hidradenitis suppurativa (HS) is associated with comorbidities that contribute to poor health, impaired life quality, and mortality risk.Objective: To provide evidence-based screening recommendations for comorbidities linked to HS.Methods: Systematic reviews were performed to summarize e...

Full description

Bibliographic Details
Published in:Journal of the American Academy of Dermatology Vol. 86; no. 5; pp. 1092 - 1102
Main Authors: Garg, Amit, Malviya, Neeta, Strunk, Andrew, Wright, Shari, Alavi, Afsaneh, Alhusayen, Raed, Alikhan, Ali, Daveluy, Steven D., Delorme, Isabelle, Goldfarb, Noah, Gulliver, Wayne, Hamzavi, Iltefat, Jaleel, Tarannum, Kimball, Alexa B., Kirby, Joslyn S., Kirchhof, Mark G., Lester, Janice, Lev-Tov, Hadar, Lowes, Michelle A., Micheletti, Robert
Format: research Journal Article
Published: Elsevier B.V. May2022
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=156288744&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 156288744
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01909622
        1ZF
      jtl: Journal of the American Academy of Dermatology
      issn: 01909622
      maglogo: N
    pubinfo:
      dt: May2022
      vid: 86
      iid: 5
      pid: 467
      pub: Elsevier B.V.
      place: New York, New York
    artinfo:
      ui:
        156288744
        156288744
        NLM33493574
        156288744
        10.1016/j.jaad.2021.01.059
        NLM33493574
        156288744
      ppf: 1092
      ppct: 10
      formats:
      tig:
        atl: Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.
      aug:
        au:
          Garg, Amit
          Malviya, Neeta
          Strunk, Andrew
          Wright, Shari
          Alavi, Afsaneh
          Alhusayen, Raed
          Alikhan, Ali
          Daveluy, Steven D.
          Delorme, Isabelle
          Goldfarb, Noah
          Gulliver, Wayne
          Hamzavi, Iltefat
          Jaleel, Tarannum
          Kimball, Alexa B.
          Kirby, Joslyn S.
          Kirchhof, Mark G.
          Lester, Janice
          Lev-Tov, Hadar
          Lowes, Michelle A.
          Micheletti, Robert
        affil: Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York
      sug:
        subj:
          Hidradenitis Suppurativa Epidemiology
          Pyoderma Gangrenosum Epidemiology
          Hidradenitis Suppurativa Etiology
          Hidradenitis Suppurativa Diagnosis
          Female
          Comorbidity
          Canada
          Human
          Ferrans and Powers Quality of Life Index
          Questionnaires
          Funding Source
          Female
      ab: Background: Hidradenitis suppurativa (HS) is associated with comorbidities that contribute to poor health, impaired life quality, and mortality risk.Objective: To provide evidence-based screening recommendations for comorbidities linked to HS.Methods: Systematic reviews were performed to summarize evidence on the prevalence and incidence of 30 comorbidities in patients with HS relative to the general population. The screening recommendation for each comorbidity was informed by the consistency and quality of existing studies, disease prevalence, and magnitude of association, as well as benefits, harms, and feasibility of screening. The level of evidence and strength of corresponding screening recommendation were graded by using the Strength of Recommendation Taxonomy (SORT) criteria.Results: Screening is recommended for the following comorbidities: acne, dissecting cellulitis of the scalp, pilonidal disease, pyoderma gangrenosum, depression, generalized anxiety disorder, suicide, smoking, substance use disorder, polycystic ovary syndrome, obesity, dyslipidemia, diabetes mellitus, metabolic syndrome, hypertension, cardiovascular disease, inflammatory bowel disease, spondyloarthritis, and sexual dysfunction. It is also recommended to screen patients with Down syndrome for HS. The decision to screen for specific comorbidities may vary with patient risk factors. The role of the dermatologist in screening varies according to comorbidity.Limitations: Screening recommendations represent one component of a comprehensive care strategy.Conclusions: Dermatologists should support screening efforts to identify comorbid conditions in HS.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N